For patients with metastatic HER2-positive gastric cancer, the KEYNOTE-811 trial demonstrated that adding pembrolizumab to first-line therapy significantly improved PFS when used in conjunction with trastuzumab and chemotherapy12. The gene discussed is ERBB2; the disease is gastric cancer.